Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
5 Cards in this Set
- Front
- Back
Tacrine
|
Anticholinesterase agent (alz)
-modest beneficial effect -requires 4x/day dosing -additional hepatotoxicity complicates use of drug (frequent liver fxn test) |
|
Donepezil
|
Anticholinesterase agent (alz)
-only modest beneficial effect -pretty much put tacrine out of business -very long half life allows q day (hs) dosing. (1x/day) best S/E profile: no hepatotoxicity -CURRENT DRUG OF CHOICE for new alz patients |
|
Rivastigmine
|
Anticholinesterase agent (alz)
-only modest beneficial effect -bid dosing with meals -most problematic for cholinergic s/e -new transdermal dose form -used for people who don't respond to other drugs or have built up tolerance |
|
Galantamine
|
Anticholinesterase agent (Alz)
-only modest beneficial effect -bid dosing with meals -use for people who don't respond to other med or built tolerance -S/E incidence fewer than Rivastigmine, more than Donepezil |
|
Memantine
|
NMDA antagonist (Alz)
-usually added as 2nd agent -indicated for moderate to severe AD -well absorbed orally -little metabolized: excreted unchanged (be careful with renal failure patients) -long half life = 1x/day dose or bid -takes long time to get to "steady state" -bettter tolerated than anticholinesterase drugs |